SARS-CoV-2 (Spike) Antibody, Quantitative

The SARS-CoV-2 (Spike) Antibody, Quantitative test measures the concentration of IgG antibodies directed against the virus spike (S) protein, providing a numeric result that reflects humoral immune response after vaccination or natural infection. The assay is performed in an accredited laboratory using validated immunoassay methods (eg, CLIA/ELISA) and reported in standardized units to allow comparison over time.

This at‑home Lab‑at‑Home service in Dubai is useful for monitoring vaccine response, assessing waning immunity, and supporting clinical decisions about booster doses—especially for older adults, healthcare workers, and immunocompromised individuals. Results should be interpreted alongside clinical history and local UAE guidelines; antibody level alone does not guarantee complete protection against infection.

• SARS-CoV-2 (Spike) IgG — Quantitative
• Antibody concentration (BAU/mL or AU/mL)
• Test method — CLIA/ELISA
• Reference cutoff / qualitative interpretation (positive / negative)

• 2–6 weeks after completion of primary vaccination series to assess peak response
• Before or when considering a booster dose to evaluate need
• 3–6 months post-vaccination to monitor waning immunity
• After suspected breakthrough infection to document post‑infection response
• Regular monitoring for immunocompromised or high‑risk individuals

• Quantitative result to track antibody levels over time
• At‑home sample collection by trained phlebotomist in Dubai
• Fast processing in accredited UAE laboratories with clear numeric report
• Supports informed decisions about boosters and clinical follow‑up
• Useful for people with chronic conditions, healthcare workers, and seniors

• Home blood collection (venous sample) performed by certified phlebotomist
• No fasting required; stay hydrated before collection
• Provide Emirates ID at time of sample collection for verification
• Inform collector of recent vaccination date or any recent COVID‑19 symptoms